Agilent Technologies, IncNYSE: A
Health Care · Life Sciences Tools & Services
$114.69
-0.74%
Vol: 909K
Research Digest
Friday, May 1, 2026
Agilent Technologies announced Q2 FY2026 earnings release for May 27 and scheduled investor day, with recent FDA approval for companion diagnostic and strategic M&A activity.
Agilent will announce Q2 FY2026 results on May 27, 2026 followed by investor conference call. Recent highlights include FDA approval for PD-L1 IHC 22C3 pharmDx companion diagnostic, launch of BioTek Cytation 9 cell imaging platform, and establishment of Agilent Advanced Therapeutics unifying CDMO capabilities across Canada and US. Plans to acquire Biocare Medical for clinical and research pathology solutions. FY2025 revenue was $6.95 billion. Stock currently at $110.85 with P/E of 25.33.
Previous Market Intelligence
13 daysApr 30Agilent Technologies receives FDA approval for companion diagnostic and launches new cell imaging productNeutral▶
Agilent Technologies received FDA approval for PD-L1 IHC 22C3 pharmDx companion diagnostic for identifying esophageal and gastroesophageal carcinoma patients eligible for KEYTRUDA. Launched BioTek Cytation 9 cell imaging multimode reader combining microplate reading and high-content imaging. Presented cancer research technologies and collaborations at AACR Annual Meeting in April. Q2 FY2026 earnings scheduled for May 27. Company generated $6.95 billion revenue in fiscal 2025 with approximately 18,000 employees. Stock trading around $116 navigating volatile market.
Apr 29No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 16Agilent showcases cancer research solutions at AACR 2026 April 17-22; Barclays adjusts price target to $140 from $150; maintains Overweight.Neutral▶
Agilent Technologies will present new cancer research technologies and scientific collaborations at the American Association for Cancer Research Annual Meeting April 17-22 in San Diego. Featured technologies include BioTek Cytation 9 cell imaging reader and collaboration with Oxford Nanopore Technologies. Barclays adjusted price target to $140 from $150 while maintaining Overweight rating. Sumitomo Mitsui Trust reduced stake by 4.9% in Q4. FY2025 revenue $6.95B.
Apr 15Agilent FDA-approves expanded PD-L1 cancer diagnostic; Supreme Court upholds CRISPR patent invalidations.Mixed▶
Agilent Technologies secured FDA approval for expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication and launched BioTek Cytation 9 cell imaging reader. U.S. Supreme Court let stand rulings invalidating two Agilent CRISPR-related patents. FY2026 revenue guidance: $7.3B-$7.5B.
Apr 14Agilent receives FDA approval for expanded PD-L1 cancer diagnostic indication.Positive▶
Agilent Technologies secured FDA approval for expanded use of its PD-L1 IHC 22C3 pharmDx companion diagnostic, now approved for first-line use of Keytruda in epithelial ovarian carcinoma and other hard-to-treat cancers. The company also introduced the BioTek Cytation 9 cell imaging multimode reader. However, the U.S. Supreme Court let stand rulings invalidating two CRISPR-related patents.
Apr 13Agilent Technologies faces China headwinds with 21% market decline, prompting full-year outlook revision, though clinical business shows 50% order growth.Mixed▶
Agilent faces significant business challenges in China (declined 21%), prompting revised full-year outlook to reflect double-digit decline. Clinical business strong with approximately 50% order growth. Book-to-bill ratio exceeding 1.0x. Fifteen analysts maintain Buy consensus with $161.20 average target. Declared quarterly dividend of $0.255 payable April 22.
Apr 10Agilent Technologies announces co-marketing partnership with BaseSolve for integrated NGS workflow; FDA expands diagnostic approval.Positive▶
Agilent Technologies and BaseSolve Informatics announced a U.S.-focused co-marketing agreement to deliver integrated Next-Generation Sequencing workflows. The company secured FDA approval for expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication. Consensus analyst recommendation is Moderate Buy with average price target of $161.20.
Apr 9Agilent Technologies opens India refurbishment center advancing sustainable science and innovationNeutral▶
Agilent Technologies opened an India Refurbishment Center to advance sustainable science and affordable innovation. The company generated revenue of $6.51 billion in fiscal 2024 and employs 18,000 people worldwide. The company continues to innovate with new product launches and maintains a positive long-term revenue forecast despite navigating challenges from recent CRISPR patent setbacks and mixed earnings results. Agilent specializes in life sciences, diagnostics and applied markets.
Apr 8No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 7Agilent to acquire Biocare Medical for $950M; Q1 FY2026 revenue +7%; raised FY2026 guide.Mixed▶
Agilent definitive agreement to acquire Biocare Medical (pathology antibody) for $950M cash, close Q4 FY26. Q1 FY26 revenue $1.80B (+7% reported, +4.4% core). Raised FY26 guide to $7.3-7.5B (+5.5-7.5%). Showcased automated workflows at SLAS2026.
Apr 6Agilent Navigates CRISPR Patent Setback; BioTek Cytation 9 LaunchNeutral▶
Agilent Technologies faces challenges from recent CRISPR patent setback while launching new BioTek Cytation 9 platform. Stock at $115.48 with market cap of $32.63B. Mixed analyst outlook with average 12-month price target of $163.19 suggesting 41% upside. YTD decline of 17% reflects market caution. Company operates through Life Sciences, Agilent CrossLab, and Applied Markets segments.
Apr 3Agilent acquires Biocare Medical for $950M to expand clinical pathology portfolio with double-digit growth platform.Positive▶
Agilent Technologies announced a definitive agreement to acquire Biocare Medical in an all-cash transaction valued at $950 million. The acquisition expands Agilent's pathology portfolio with a complementary antibody, reagent, and instrument business. Expected to close by Q4 fiscal 2026. Agilent also declared a quarterly dividend of $0.255 per share and reaffirmed FY 2026 revenue guidance of $7.3-7.5 billion.
Apr 2No significant overnight updates; Agilent Technologies trading at $111.75; recently opened India Refurbishment Center and acquired Biocare Medical.Neutral▶
Agilent Technologies trading at $111.75 with modest recent activity. Company recently opened India Refurbishment Center and acquired Biocare Medical for cancer diagnostics expansion. No major overnight news from the last 24 hours.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $469.56 | -1.96% | -1.9% | 17.5x | 0.97 | $178.0B |
| DHRDANAHER | $175.47 | -1.95% | -6.9% | 19.7x | 0.99 | $126.7B |
| AAGILENT | $114.69 | -0.74% | +0.6% | 17.6x | 1.30 | $32.7B |
| WATWATERS | $306.56 | -0.86% | +1.7% | 18.9x | 1.20 | $30.4B |
| IQVIQVIA | $157.04 | -0.84% | -7.2% | 11.3x | 1.39 | $26.6B |
| MTDMETTLER | $1,269.64 | -0.55% | +0.8% | 24.9x | 1.44 | $25.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.